A phase I/II exploratory clinical trial for intracordal injection of recombinant hepatocyte growth factor for vocal fold scar and sulcus
- 30 October 2017
- journal article
- research article
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 12 (4), 1031-1038
- https://doi.org/10.1002/term.2603
Abstract
Vocal fold scar and sulcus are intractable diseases with no effective established treatments. Hepatocyte growth factor (HGF) has preclinically proven to have potent antifibrotic and regenerative effects on vocal fold scar. The current Phase I/II clinical trial aims to examine the safety and effectiveness of intracordal injection of a recombinant human HGF drug for patients with vocal fold scar or sulcus. This is an open‐label, dose‐escalating, first‐in‐human clinical trial. Eighteen patients with bilateral vocal fold scar or sulcus were enrolled and divided into three groups: Step I received 1 μg of HGF per vocal fold; Step II received 3 μg of HGF; and Step III received 10 μg of HGF. Injections were administered once weekly for 4 weeks. The protocol treatment was performed starting with Step I and escalating to Step III. Patients were followed for 6 months post‐treatment. Local and systemic safety aspects were examined as primary endpoints, and therapeutic effects were assessed as secondary endpoints using voice handicap index‐10; maximum phonation time; vocal fold vibratory amplitude; grade, rough, breathy, asthenic, strained scale; and jitter. The results indicated no serious drug‐related adverse events in either the systemic or local examinations. In whole‐subject analysis, voice handicap index‐10, vocal fold vibratory amplitude, and grade, rough, breathy, asthenic, strained scale were significantly improved at 6 months, whereas maximum phonation time and jitter varied. There were no significant differences in phonatory data between the step groups. In conclusion, intracordal injection of a recombinant human HGF drug was safe, feasible, and potentially effective for human patients with vocal fold scar or sulcus.Keywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 23 references indexed in Scilit:
- Optimal Duration for Voice Rest After Vocal Fold Surgery: Randomized Controlled Clinical StudyJournal of Voice, 2016
- Histologic Characterization of Human Scarred Vocal FoldsJournal of Voice, 2009
- Current treatment of vocal fold scarringCurrent Opinion in Otolaryngology & Head and Neck Surgery, 2005
- Growth Factor Therapy for Vocal Fold Scarring in a Canine ModelAnnals of Otology, Rhinology & Laryngology, 2004
- Roles of Hepatocyte Growth Factor and Transforming Growth Factor β1 in Production of Extracellular Matrix by Canine Vocal Fold FibroblastsThe Laryngoscope, 2003
- Hepatocyte Growth Factor and its Receptor C-Met in Rat and Rabbit Vocal FoldsAnnals of Otology, Rhinology & Laryngology, 2002
- Growth Factor Therapy to Improve Soft Tissue HealingFacial Plastic Surgery, 2002
- Vocal fold proteoglycans and their influence on biomechanicsThe Laryngoscope, 1999
- Morphological Structure of the Vocal Cord as a Vibrator and its VariationsFolia Phoniatrica et Logopaedica, 1974
- Pitch Perturbations in Normal and Pathologic VoicesFolia Phoniatrica et Logopaedica, 1970